Related Experiment Videos
Beta-2 adrenergic agonists: focus on safety and benefits versus risks
Victor E Ortega1, Stephen P Peters
1Wake Forest University Health Sciences, Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, NC, United States. vortega@wfubmc.edu
Current Opinion in Pharmacology
|May 11, 2010
Summary
Concerns about beta agonists and asthma death risk in the 1960s involved outdated short-acting beta agonists (SABAs). Modern long-acting beta agonist (LABA) therapy, especially with inhaled corticosteroids (ICS), shows significant benefits outweighing rare risks.
Area of Science:
- Pharmacology and Therapeutics
- Respiratory Medicine
- Clinical Trials and Meta-Analyses
Background:
- Historical concerns regarding beta-2 adrenergic receptor agonists (beta agonists) and asthma mortality emerged in the 1960s, linked to obsolete short-acting beta agonist (SABA) formulations.
- Subsequent research suggested potential for severe adverse events with long-acting beta agonist (LABA) therapy, though study designs underpinning these conclusions were often suboptimal.
Purpose of the Study:
- To critically evaluate the safety profile of long-acting beta agonist (LABA) therapy in asthma management.
- To assess the risk-benefit ratio of combining LABA with inhaled corticosteroids (ICS) in clinical practice.
Main Methods:
- Review of historical data concerning short-acting beta agonist (SABA) use and asthma mortality.
- Analysis of prospective clinical trials and meta-analyses investigating long-acting beta agonist (LABA) therapy, particularly in combination with inhaled corticosteroids (ICS).
- Evaluation of study designs and statistical power for assessing rare adverse events.
Main Results:
- Early concerns about beta agonists and asthma death were associated with outdated SABA preparations no longer in use.
- Evidence suggests that while LABA therapy may have potential risks, the foundational studies are often limited by suboptimal design.
- Multiple prospective trials and meta-analyses demonstrate significant clinical benefits when LABA is used in combination with ICS.
Conclusions:
- The combination of long-acting beta agonists (LABA) and inhaled corticosteroids (ICS) offers substantial clinical advantages for asthma management.
- The benefits of LABA/ICS therapy appear to outweigh the rare risks of serious or life-threatening adverse events, despite limitations in definitive statistical power for rare events.
- Historical safety concerns related to older SABAs do not directly translate to current LABA/ICS treatment paradigms.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...